- Das Lesen ist schön


€ 0,00 0 Buch dabei,
DNA Topoisomerases in Cancer Therapy als Buch

DNA Topoisomerases in Cancer Therapy

Present and Future. Auflage 2003. Book. Sprache: Englisch.
Buch (gebunden)
This volume commemorates the 30th anniversary of the discovery in 1971 of the first DNA topoisomerases, i.e topoisomerase I in E. coli, then provisionally named `omega' protein, by the pioneering work of Jim Wang at Harvard University, who has contri... weiterlesen


inkl. MwSt.
Lieferbar innerhalb von zwei bis drei Werktagen
DNA Topoisomerases in Cancer Therapy als Buch
Titel: DNA Topoisomerases in Cancer Therapy

ISBN: 0306477440
EAN: 9780306477447
Present and Future.
Auflage 2003.
Sprache: Englisch.
Herausgegeben von Toshiwo Andoh
Springer US

30. Juni 2003 - gebunden - 220 Seiten


This volume commemorates the 30th anniversary of the discovery in 1971 of the first DNA topoisomerases, i.e topoisomerase I in E. coli, then provisionally named `omega' protein, by the pioneering work of Jim Wang at Harvard University, who has contributed an article to this volume: `Reflections on an accidental discovery' of the enzyme. Many kinds of topoisomerase have since been found from type I through to type VI in a variety of organisms ranging from viruses to higher eukaryote mammals. The wide distribution of enzymes in various forms of life implies that the DNA topoisomerase is essential for life. In the mid 80's type I and II enzymes were found to be the intracellular targets of a number of efficacious anticancer drugs such as doxorubicin, mitoxantrone, etoposide and camptothecin as a result of a continued efforts of many investigators, especially Leroy Liu and his collaborators at Johns Hopkins University. Readers will find a series of chapters written by researchers actively engaged in the expanding field of topoisomerase and their inhibitors. The series of chapters cover review articles on pharmacology and the molecular mechanism of topoisomerase I- and II-targeting anticancer drugs in mammals and in the yeast Saccharomyces cerevisiae, which has proved to be a superb model organism for studies of anticancer drugs. This volume compiles up-to-date information on the topoisomerase-targeting compounds in clinical and preclinical development as a useful and important reference book for students and researchers in the field of pharmacology, toxicology, oncology and molecular biology.


Contributors. Preface.
1: Reflections on an accidental discovery; J.C. Wang. 1. A hectic year in the late 1960s. 2. An accidental finding. 3. A new enzyme. 4. An enzyme in search of a name. 5. A discovery missed? Postscripts. References.
2: Pharmacology of topoisomerase inhibitors; Y. Sasaki. 1. Introduction. References.
3: Mechanisms of topoisomerase I inhibition by anticancer drugs; Y. Pommier, J. Barceló, T. Furuta, H. Takemura, O. Sordet. 1. Introduction. 2. Molecular model for top1 inhibition: misalignment of the 5'-hydroxyl end of the cleaved DNA. 3. Cellular lesions induced by top1 cleavage complex. 4. Repair of top1 covalent complexes. 5. Molecular pathways implicated in the cellular responses to top1 cleavage complexes; determinants of response and resistance with potential clinical relevance. 6. Apoptotic response to top1 poisoning: balance between cell death and survival. References.
4: Mechanism of action of topoisomerase II-targeted anticancer drugs; K.D. Bromberg, N. Osheroff. Abstract. 1. Introduction. 2. Topoisomerase II. 3. Topoisomerase II-mediated DNA cleavage and ligation. 4. Topoisomerase II-targeted anticancer drugs. 5. Conclusions and perspectives. Acknowledgements. References.
5: Degradation of topoisomerase cleavable complexes; L.F. Liu. Text. References.
6: Yeast as a model system in the analysis of DNA topoisomerase I poisons; H.R. Jacquiau, M.-A. Bjornsti. 1. Introduction.2. Saccharomyces cerevisiae as an experimental system. 3. DNA topoisomerase I mutants. 4. Cellular responses to Top1 poisons. 5. Conclusions. Acknowledgements. References.
7: Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms; M. Malik, J.L. Nitiss. 1. Introduction. 2. How the enzyme works. 3. Understanding topoisomerase II biology using yeast. Dissecting the action of topoisomerase II targeting agents: Poisons and catalytic inhibitors. 4. Resistance to topoisomerase II targeting drugs: Changes at the enzyme level. 5. Resistance to topoisomerase II targeting drugs: Studying human enzymes in yeast. 6. Cell killing pathways downstream of covalent complex formation. 7. Perspectives and unanswered questions. Acknowledgements. References.
8: Cellular resistance to DNA topoisomerase I-targeting drugs; K. Yanase, T. Andoh. 1. Introduction. 2. Pretarget events. 3. Drug-target interactions. 4. Post-target events. References.
9: Development of new topoisomerase I-targeting compounds as candidate anticancer drugs; Y. Pommier, ZhiYong Liao, LingHua Meng. 1. Novel Topoisomerase I Inhibitors. 2. Novel camptothecins and homocamptothecins. 3. Rationale for developing non-camptothecin top1 inhibitors. 4. Non camptothecin top1 poisons: polyheterocyclic aromatic inhibitors. 5. Non camptothecin top1 poisons: minor groove binding inhibitors. 6. Proposed common molecular mechanism for trapping top1-DNA complexes by
089 - 70 80 99 47

Mo. - Fr. 8.00 - 20.00 Uhr
Sa. 10.00 - 20.00 Uhr
089 - 30 75 75 75

Mo. - Sa. 9.00 - 20.00 Uhr
Bleiben Sie in Kontakt:
Sicher & bequem bezahlen:
akzeptierte Zahlungsarten: Überweisung, offene Rechnung,
Visa, Master Card, American Express, Paypal
Zustellung durch:
* Alle Preise verstehen sich inkl. der gesetzlichen MwSt. Informationen über den Versand und anfallende Versandkosten finden Sie hier.
** im Vergleich zum dargestellten Vergleichspreis.